🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Shout out to John Yeakel, MD for recent report of the utility of aggressive follow up with ctDNA in Merkel cell! pubmed.ncbi.nlm.nih.gov/34869814/

Nice data from LaIT SABR, an analysis of >1000 colorectal lung mets. The highest RT doses associated with not only excellent local control, but also with delay to more widespread metastatic disease. sciencedirect.com/science/articl…

Our case-based survey of IASLC is out! doi.org/10.1016/j.cllc… For stage III NSCLC, molecular status is already impacting local therapy choice, despite the lack of OS data (or any data for ALK). A lot of extrapolation is being used in the clinic. Need more comparative studies!

Attn ALL M3 students! Please join us at @UCIrvineSOM's Virtual Residency Open House and learn about all the programs UCI has including radonc. Great speakers include Dean @DocMBO and @DeanStamosUCI! RSVP at: som.uci.edu/gme/residency-…

COAST trial: exciting data for stage III NSCLC, combining durvalumab with either anti-NKG2A or anti-CD79 ab's after completion of chemoradiaiton resulted in dramatic improvement in PFS.

Dr. Riviere's report on comorbid immunosuppression in the setting of Merkel cell. At a time when immunotherapy gains are growing, need to think about this population (solid organ transplant recipients in particular!) authors.elsevier.com/sd/article/S26… Justin Moyers

This is the science we are here for. Groundbreaking #ASTRO22 presentation by Erin Gillespie, MD MPH in RANDOMIZED trial for asymptomatic #bonemets with reduced #SRE and improved overall survival.ASTRO #wow

Dr Harada teaching us about the possibility of increased esophagitis with concurrent TKI with thoracic RT. 🤔interesting work!! Eric Ku John Yeakel, MD Akul Munjal UCI Radation Oncology #ASTRO22

Proud of our chief resident John Yeakel, MD presenting our UCI Y-90 experience at #ASTRO22 for oligometastatic liver mets! Manuscript to come soon! UCI Radation Oncology

Great work Dr Ku and your project on lymphopenia after radiation! Thought provoking in the era of imrt :) Eric Ku John Yeakel, MD Steven Seyedin UCI Radation Oncology

Exciting update on CURB for oligoprogressive disease. For NSCLC, dramatic increase in PFS (10 vs 2 mo) and time before needing next line therapy (11 vs 5 mo). Could be explained by decr in VAF and pattern of failure Misako Nagasaka Steven Seyedin

Very cool to hear Dr Nagasaka’s expertise recognized. For any Japanese speakers check out her recent IASLC podcast Misako Nagasaka IASLC

Very excited to have Dr. Krishna Hanubal joining our residency team in 2024!! Steven Seyedin @ErinHealyMD UCI Radation Oncology Allen Chen MD John Yeakel, MD Jino Park

Great work Dr. Ku outlining lymphocyte nadir following RT for sarcoma. Seems to correspond well with outcomes, with bone V10Gy being the strongest predictor for ALC drop advancesradonc.org/article/S2452-…

Great work to our residents at Astro! Steven Seyedin UCI Health Physicians UCI Health @ErinHealyMD